CD8+ T Lymphocyte Subsets in Bladder Tumor Draining Lymph Nodes
(ندگان)پدیدآور
Faghih, ZahraSadat Shobeiri, SaeidehAriafar, AliSarkarian, MohsenZeighami, ShahryarNazari, NazaninAbbasi-Sarvak, SaeedErfani, Nasrollah
نوع مدرک
TextOriginal Article
زبان مدرک
Englishچکیده
Background: Cytotoxic CD8+ T cells, as essential parts of the adaptive immune
system, play pivotal roles in anti-tumor immune responses. It is well documented that
cytokine expression profiles and activation status of these cells during anti-tumor
immune responses affect the outcome of host-tumor interaction. Objective: To
investigate the percentages of CD8+ lymphocytes and their subsets in tumor draining
lymph nodes of patients with bladder cancer. Methods: Forty-five patients with bladder
cancer, candidate for radical cystectomy, were recruited. Mononuclear cells were
isolated from draining lymph nodes using Ficoll-Hypaque gradient centrifugation, and
were activated by PMA/Ionomycin in the presence of Golgi inhibitors. The cells were
then permeabilized and stained with appropriate flourochrome conjugated antibodies
against CD3, CD8, IFN-γ, IL-17 and IL-4 molecules. Data were collected on a fourcolor
flow cytometer and analyzed by CellQuestPro software. Results: Despite no
difference in the frequency of IL-17 producing CD8+ (Tc17) lymphocytes, the mean
expression of IL-17 in this subset was significantly elevated in high-grade patients
(p=0.011). The percentage of double positive IFN-γ/IL-17 CD8+ lymphocytes was also
significantly increased in node positive patients compared to node negative ones
(p=0.046). Our results also demonstrated that the percentage of IFN-γ producing CD8+
(Tc1) lymphocytes was significantly increased in the patients with higher histological
grade compared to those with lower ones (p=0.038). Conclusion: IFN-γ and IL-17
producing CD8+ T cells may increase in advanced stages of bladder cancer, but their
correlation with tumor prognosis remains to be investigated.
کلید واژگان
Bladder CancerLymph Node
CD8+ lymphocytes
Tc1
Tc2
Tc17
شماره نشریه
4تاریخ نشر
2016-12-011395-09-11
ناشر
Shiraz Institute for Cancer Researchسازمان پدید آورنده
Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranCancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Urology-Oncology Research Center,Shiraz University of Medical Sciences, Shiraz, Iran
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
Urology-Oncology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
شاپا
1735-13831735-367X



